

Hao Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1961840/publications.pdf>

Version: 2024-02-01

13
papers

188
citations

1163117

8
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

295
citing authors

#	ARTICLE	IF	CITATIONS
1	Exosomes: Potential executors of IL-35 gene-modified adipose-derived mesenchymal stem cells in inhibiting acute rejection after heart transplantation. <i>Scandinavian Journal of Immunology</i> , 2022, 96, e13171.	2.7	2
2	Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma. <i>Clinical and Experimental Immunology</i> , 2021, 203, 219-229.	2.6	13
3	Interleukin-35: An emerging player in the progression of liver diseases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101518.	1.5	2
4	Identification and Validation of an 6-Metabolism-Related Gene Signature and Its Correlation With Immune Checkpoint in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 783934.	2.8	3
5	Inhibition of cardiac allograft rejection in mice using interleukin-35-modified mesenchymal stem cells. <i>Scandinavian Journal of Immunology</i> , 2019, 89, e12750.	2.7	14
6	Interleukin-35 Gene-Modified Mesenchymal Stem Cells Protect Concanavalin A-Induced Fulminant Hepatitis by Decreasing the Interferon Gamma Level. <i>Human Gene Therapy</i> , 2018, 29, 234-241.	2.7	34
7	Mesenchymal stem cells overexpressing IL-35: a novel immunosuppressive strategy and therapeutic target for inducing transplant tolerance. <i>Stem Cell Research and Therapy</i> , 2018, 9, 254.	5.5	16
8	Mesenchymal stem cell expression of interleukin-35 protects against ulcerative colitis by suppressing mucosal immune responses. <i>Cytotherapy</i> , 2018, 20, 911-918.	0.7	20
9	Mesenchymal Stem Cells Overexpressing Interleukin-35 Propagate Immunosuppressive Effects in Mice. <i>Scandinavian Journal of Immunology</i> , 2017, 86, 389-395.	2.7	20
10	Effects of Platelet-Derived Endothelial Cell Growth Factor and Doppler Perfusion Index in Patients with Colorectal Hepatic Metastases. <i>Visceral Medicine</i> , 2016, 32, 206-210.	1.3	1
11	Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 799-806.	1.8	36
12	Artificial antigen-presenting cells expressing AFP158-166 peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes. <i>Oncotarget</i> , 2016, 7, 17579-17590.	1.8	6
13	Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice. <i>Transplant Immunology</i> , 2013, 29, 99-104.	1.2	21